MNMD - What's Going On With MindMed Stock Thursday? | Benzinga
Mind Medicine Inc (NASDAQ:MNMD) shares are trading higher Thursday after the company received FDA breakthrough therapy designation and announced positive study data.
What Happened: MindMed announced that the FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder.
The company also announced that its Phase 2b study of MM120 in generalized anxiety disorder met its key secondary endpoint. 12-week topline data demonstrated “clinically and statistically significant durability of activity” observed through week 12, MindMed said.
“The FDA’s decision to designate MM120 as a breakthrough therapy for GAD and the durability data from our Phase 2b study provide ...